Crown ElectroKinetics Corp. (CRKN)
NASDAQ: CRKN · IEX Real-Time Price · USD
0.0509
+0.0009 (1.80%)
At close: Apr 26, 2024, 4:00 PM
0.0510
+0.0001 (0.20%)
After-hours: Apr 26, 2024, 7:59 PM EDT

Company Description

Crown Electrokinetics Corp. develops and sells optical switching films in the United States.

It offers DynamicTint technology, which allows transition between clear and dark in seconds that can be applied to a wide array of windows including commercial buildings, automotive sunroofs, and residential skylight, and windows.

The company was formerly known as 3D Nanocolor Corp. and changed its name to Crown ElectroKinetics Corp. in October 2017.

Crown ElectroKinetics Corp. was incorporated in 2015 and is headquartered in Corvallis, Oregon.

Crown ElectroKinetics Corp.
Crown ElectroKinetics logo
Country United States
Founded 2015
Industry Specialty Chemicals
Sector Materials
Employees 42
CEO Douglas B. Croxall

Contact Details

Address:
1110 Ne Circle Blvd
Corvallis, Oregon 97330
United States
Phone 800-674-3612
Website crownek.com

Stock Details

Ticker Symbol CRKN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001761696
CUSIP Number 228339206
ISIN Number US2283393054
Employer ID 47-5423944
SIC Code 3679

Key Executives

Name Position
Douglas B. Croxall Chairman and Chief Executive Officer
Timothy Koch Co-Founder and Chief Technology Officer
Joel Krutz Chief Operating Officer, Chief Financial Officer and Director
Leonardo Perez Senior Vice President and GM
Corey Boaz President of Construction of Fiber Optics Division and Crown Fiber Optics

Latest SEC Filings

Date Type Title
Apr 1, 2024 10-K Annual Report
Mar 8, 2024 8-K Current Report
Feb 9, 2024 EFFECT Notice of Effectiveness
Feb 9, 2024 424B4 Prospectus
Feb 7, 2024 UPLOAD Filing
Feb 5, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Jan 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2023 10-Q Quarterly Report
Oct 23, 2023 8-K Current Report
Sep 26, 2023 424B5 Filing